JPRN-UMIN000008289已完成2 期
Study of new therapy in patients with chronic hepatitis C including liver cirrhosis - Study of new therapy in patients with chronic hepatitis C including liver cirrhosis
niversity of Tsukuba0 个研究点目标入组 10 人开始时间: 2012年7月2日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patient with acute hepatitis (2)Patient with severe liver dysfunction whose serum liver function test is 5 fold higher than normal range, especially, AST or ALT is 2 fold higher than normal range (3)HIV patient (4)Patient with shunt from portal vein to inferior vena cava (5)Serum total bilirubin concentration is more than 3.0 mg/dl (6)Past history of severe stroke or severe heart disease (7)Bone marrow transplantation recipient or patients with immunodeficiency (8)Patient with IgA or other plasma protein deficiency (9)Patient with severe pulmonary, renal, gastroenterology, hematology or psycho-neurologic disease (10)Serum HbA1c concentration is more than 8.0 (NGSP) (11)Patient with hepatocellular carcinoma or another malignancy (12)Woman with pregnancy or willing to get pregnant (13)Patient who received platelet transfusion in previous 2 weeks (14)Patient who are administered albumin preparation in previous 6 months (15)Past history of splenectomy or partial splenic embolization (16)Past history of drug allergies (17)Past history of thromboembolism (18)Patient whose doctor determined as inadequate for the study
研究者
相似试验
已完成
不适用
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C USING ALFA 2B INTERFERON ASSOCIATED WITH RIBAVIRINE, COMPARING IT WITH THE SAME SCHEME PREVIOUS FROM DAILY ADMINISTRATION FOR 2 WEEKS OF ALFA 2 B INTERFEROPER-014-98SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (HCC) USING PEG-INTERFERON ALPHA 2B AND RIBAVIRINEPER-039-01SCHERING PLOUGH RESEARCH INSTITUTE,
已完成
不适用
Therapeutic vaccination in patients with chronic hepatitis C genotype 1 using four courses of 8 + 6 + 6 + 6 intramuscular injections of 50 µg E1y at 3 week intervals: a multicenter, 3:1 randomized, double-blind, placebo-controlled, parallel-group study over 157 weeks in 122 patientsHepatitisISRCTN71794661Innogenetics NV (Belgium)122
尚未招募
2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis BACTRN12614000628640Gilead Sciences, Inc.150
已完成
不适用
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)Chronic Hepatitis C InfectionNCT02578693Humanity and Health Research Centre1,210
